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stroke event incidence between groups was analyzed descrip-
tively and through a multivariate logistic regression analysis after
controlling for differences in baseline clinical and demographic
variables. RESULTS: Among 8176 study patients (3493 AM;
4683 IAM), AM patients were signiﬁcantly older [51.4  9.1
and 50.0  9.6 years, p < 0.01] and comprised of fewer males
(43.2% vs. 56.2%; p < 0.01). AM patients were more likely to be
at lower risk status at index date versus IAM patients (63% vs.
28%; p < 0.01), and had a signiﬁcantly lower Deyo-Charlson
comorbidity score (0.32  0.56 vs. 0.20  0.44; p < 0.01).
During follow-up, fewer AM patients experienced a stroke event
versus IAM patients (0.7% vs. 1.1%; p = 0.03) and thereby were
36% less likely to have a stroke event (OR: 0.64, 95% CI:
0.44–0.93; p < 0.01). CONCLUSION: Adhering to clinical
guideline treatment recommendations was likely to be associated
with subsequent stroke reductions and possible long-term cost
savings in this managed care population.
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OBJECTIVE: Injectable nicardipine is increasingly used in man-
aging neurovascular conditions. To understand its place in
therapy, we conducted an evidenced-based literature review.
METHODS: The English-language literature in OVID and
Cochrane databases was searched using combinations of these
terms: intracerebral hemorrhage (ICH), neurology, neurosurgery,
nicardipine, stroke, subarachnoid hemorrhage (SAH). Two-
hundred and twenty-three abstracts were identiﬁed; after inde-
pendent review by two individuals, four clinical guidelines, two
meta-analyses, and four randomized controlled trials (RCT) were
deemed relevant. RESULTS: In clinical guidelines, based on
expert opinion, nicardipine was recommended to manage
hypertension in 1) ischemic stroke patients eligible for acute
reperfusion therapy (alternatives: labetalol, nitropaste, and nitro-
prusside); and 2) ICH (alternatives: enalapril, esmolol, hydrala-
zine, labetalol, nitroprusside, nitroglycerin). In a meta-analysis,
nicardipine had no effect on death or dependency in patients with
aneurysmal SAH [RR:0.97 (95%CI:0.78–1.20)]; adverse events
were higher versus placebo [hypotension:34% vs. 5%; phlebi-
tis:22% vs. 5%; pulmonary edema + azotemia: 6% vs. 2%]. In
acute traumatic brain injury, nicardipine had no impact on death
and severe disability [RR:0.25 (95%CI:0.05–1.27)]. Nicar-
dipine’s effect on cerebral blood ﬂow was comparable to labe-
talol (+0.19  3.9 ml/100 g/min vs. -1.55  3.2 ml/100 g/min;
p = 0.39) in ICH, while it increased from baseline in SAH
patients (42.1  12.3 ml/100 g/min vs. 47  10.7 ml/100 g/min;
p < 0.05). In a craniotomy RCT, nicardipine was less effective
than labetalol in preventing emergent hypertension (50% vs.
82%; p = 0.05) and was associated with more tachycardia (20%
vs. 0%; p = 0.11), hypotension (15% vs. 0%; p = 0.23) and
higher cost ($23.65  6.62 vs. $5.23  2.0; p < 0.05). Mean
arterial pressure remained depressed 20 minutes post-infusion
compared to nitroprusside, despite lack of
cumulative nicardipine plasma levels [60  2 mmHg vs.
73  4 mmHg; p < 0.05] in spinal surgery patients. CONCLU-
SION: While nicardipine has a role in select neurovascular
indications, recommendations are based on expert opinion.
Moreover, a lack of beneﬁt has been demonstrated in meta-
analyses and RCT in other neurovascular indications, including
aneurysmal SAH and acute traumatic brain injury.
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OBJECTIVE: The current study evaluated the appropriate utili-
zation of ezetimibe add-on therapy to simvastatin and the cost-
consequences based upon the following outcomes: ezetimibe
response, LDL-C goal achievement, and switch to rosuvastatin.
METHODS: This was a retrospective review of VASDHS
medical records to identify patients with active prescriptions for
ezetimibe and simvastatin between January 1, 2004 and August
31, 2007. Base-case response was deﬁned as 10% LDL-C
reduction from baseline at study endpoint. Additional efﬁcacy
parameters included LDL-C goal achievement and switch to
rosuvastatin if LDL-C goal not met. Pre-post analyses for con-
tinuous and binomial data were performed using Wilcoxon-
ranked sum and McNemar’s tests, respectively. Cost analyses
were conducted from the payer perspective, utilizing total direct
costs. Average cost-effectiveness ratios (CER) were calculated
for (1) ezetimibe response, (2) LDL-C goal achievement, and
(3) switch to rosuvastatin. Sensitivity analyses were performed
varying the base-case response deﬁnition. RESULTS: Overall,
121 patients met inclusion. Baseline characteristics were as
follows: male 97.5%; Caucasian 78.5%; CHD 67.8%; diabetes
63.6%; symptomatic CAD 15.7%; PAD 18.2%; AAA 7.4%;
>20% 10-year risk-score 95.9%; LDL-C goal <100 mg/dL
95.9%; LDL-C goal <70 mg/dL 57.9%; and smoker 28.1%.
Pre-post comparisons showed signiﬁcant differences from base-
line LDL-C and cholesterol for both responders (p < 0.001,
p < 0.001) and non-responders (p = 0.028, p = 0.028). Overall,
88.4% of patients responded to ezetimibe, while 36% of non-
responders had their antilipemic regimen modiﬁed. In addition,
53% of patients reached LDL-C goal. Average CERs over a
9-month period using base-case response deﬁnition were:
$1705.64 per ezetimibe response, $2054.26 per LDL-C goal
achieved, and $2997.56 per switch to rosuvastatin. Sensitivity
analyses showed no change in trend for ezetimibe response, but
changes were observed for the latter parameters. CONCLU-
SION: There is beneﬁt in assessing both response rates as well as
LDL-C goal attainment when determining a cost-analysis of
ezetimibe add-on therapy to simvastatin.
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OBJECTIVE: Hyperlipidemia increases the risk for cardio-
vascular disease and control is pivotal for preventing subsequent
complications. Multidisciplinary interventions, including phar-
macists, are important for improving patients’ outcomes. Our
objective was to quantify the impact of pharmacist interventions
in enhancing patients’ clinical and humanistic outcomes.
METHODS: Two reviewers searched International Pharmaceu-
tical Abstracts, Medline, Embase, The Cochrane Central Register
of Controlled Trials, 3rd Quarter and CINAHL for pharmacist
interventions in hyperlipidemia. Quality was assessed using
Downs-Black scale. Data extracted included patients enrolled,
study characteristics, intervention type and pre- and post-
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intervention measures for LDL, HDL, triglycerides, total choles-
terol, adherence and quality-of-life. A random-effects meta-
analysis combined data between pharmacist-intervention and
standard-care groups. Chi-square tested heterogeneity of effects.
Publication bias was assessed using funnel plots and Begg-
Mazumdar statistic. RESULTS: Fifty-one studies were found; 22
met inclusion/exclusion criteria. Study settings included medical
clinic/center (n = 11), community pharmacy (n = 8), hospital
(n = 2) and patient homes (n = 1). Patient education (77%) and
medication management (73%) were most common interven-
tions. The average patient follow-up period was 9.8  6.4
months. Quality of pharmacist-intervention studies was consid-
ered “fair” (65%, SD = 6.6%). Total cholesterol was signiﬁ-
cantly reduced from baseline (34.3  10.3 mg/dL, p < 0.001)
and also signiﬁcantly above control groups (22.0  10.4 mg/dL,
p = 0.034). LDL was reduced signiﬁcantly from baseline
(38.6  12.4 mg/dL, p = 0.002); but not signiﬁcantly more than
controls (22.1  12.0 mg/dL, p = 0.065). A clinically relevant
but not statistically signiﬁcant reduction in triglycerides was
found. Patients’ adherence to pharmacotherapeutic regimens (3/9
studies reported signiﬁcant results after pharmacists’ interven-
tions) and quality of life (2/2 signiﬁcant) were considered
possibly not sensitive and possibly sensitive to pharmacist
interventions, respectively. CONCLUSION: Total cholesterol
is sensitive to pharmacist’s interventions while LDL and
triglycerides levels are possibly sensitive to those interventions.
Further research should evaluate speciﬁc determinants of
pharmacist-sensitive outcomes.
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OBJECTIVE: New members of the TNF-signaling superfamily,
osteoprotegerin (OPG) and receptor activator of nuclear
factor-kB ligand (RANKL), are thought to play an important role
in vascular calciﬁcation and bone remodeling and might repre-
sent the molecular link between arterial calciﬁcation and bone
resorption. The purpose of this study was to determine whether
OPG and/or RANKL mediate the observed association between
coronary and bone calciﬁcation in postmenopausal women.
METHODS: Among the members of the Rancho Bernardo lon-
gitudinal study, 92 postmenopausal women (aged 58–81 years)
taking estrogen therapy (ET) who underwent assessment of bone
mineral density (BMD) and coronary artery calciﬁcation (CAC)
and had serum OPG and RANKL levels measured between
1998–2002 are the basis of this report. RESULTS: Neither OPG
nor RANKL levels varied among subjects with and without CAC
in multivariate analysis. Increase in BMD at the hip was associ-
ated with decrease in CAC (OR = 0.52; 95% CI: 0.29–0.93)
independent of age, fat-free mass, HDL cholesterol, current
smoking, and use of cholesterol-lowering medications. Other
skeletal sites demonstrated a similar pattern. Addition of
RANKL and/or OPG in the model had minimal effect on the
magnitude or statistical signiﬁcance of the BMD-CAC associa-
tion. Additionally, a test of interaction indicated that RANKL
and OPG are not signiﬁcant effect modiﬁers of the association.
CONCLUSION: Serum OPG and RANKL do not account for
the observed association between bone and coronary artery
calciﬁcation among postmenopausal women using ET.
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OBJECTIVE: Beta-blocker therapy, well established in the treat-
ment of CHF, is considered contraindicated in patients with
concomitant diabetes by many physicians due to concerns of
increased incidence of hypoglycemia, worsening dyslipidemia,
and decreased insulin sensitivity. Purpose of this study is to
determine the association between beta-blocker therapy and
hospitalization in patients with chronic heart failure (CHF) and
diabetes. METHODS: The study was a retrospective analysis
utilizing the pharmacy, inpatient and outpatient claims linked
with eligibility ﬁles for persons enrolled in the Georgia Medicaid
beneﬁts through the year 2001. Patients who received both diag-
nosis of chronic heart failure and diabetes were identiﬁed. The
study cohort was further categorized into treatment and com-
parison groups according to their exposure to Beta-blocker. A
stepwise logistic regression analysis was employed to assess the
association between taking beta-blocker and hospitalization
among CHF patients with diabetes. RESULTS: Three hundred
ninety patients with beta-blocker exposure and 642 not-exposed
patients were identiﬁed. Two hundred thirty eight patients were
hospitalized and 799 had no hospitalization. Majority of the
cohort was female 788 (76.36%), black 531 (51.45%) and in the
age group of 40–65 years 966 (93.60%). Metoprolol was the
most commonly used beta-blocker with 12,149 claims (51.83%)
followed by Carvedilol 6169 (26.32%). The most common
co-morbid conditions among patients were found to be Hyper-
tension, Ischemic Heart Disease and Chronic Obstructive Pulmo-
nary Disease. Diuretics, ACE inhibitors and Digoxin use were
found to be the common concurrent therapy taken by the
patients. After controlling for factors like age, race, gender,
common co-medications and co-morbid conditions, there was no
signiﬁcant association between hospitalization and beta-blockers
use in patients with Chronic Heart Failure and Diabetes.
CONCLUSION: Despite the potential contraindication, the
utilization of beta-blocker does not lead to a higher rate of
hospitalization among CHF patients with diabetes.
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OBJECTIVE: The Blood Pressure Success Zone (BPSZ) Program
is a nationwide initiative which provides blood pressure manage-
ment education to hypertensive patients and a complimentary
trial of antihypertensive medications. The BPSZ-BLISS (Longitu-
dinal Observational Study of Success) is an observational study
to evaluate BPSZ program effectiveness on blood pressure (BP)
control, compliance, persistence and treatment satisfaction.
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